Corporate America is heading into September with an unusually strong earnings backdrop, as companies across multiple industries report resilient profits despite inflation, higher borrowing costs and continued economic uncertainty. The latest earnings season has also delivered an important message for

American suppliers are racing to expand manufacturing capacity as the U.S. data center construction boom creates a powerful new source of demand for generators, electrical equipment, cooling systems, steel and other industrial products. The rapid growth of artificial intelligence is

U.S. manufacturing reshoring is creating a new investment opportunity for industrial companies as businesses increase domestic production, strengthen supply chains and spend heavily on factories, machinery and infrastructure. The trend is gaining additional momentum from the rapid expansion of AI

U.S. biotech industry is gaining fresh momentum as personalized cancer vaccine research produces encouraging clinical results and pharmaceutical companies accelerate efforts to develop next-generation cancer treatments. The progress is strengthening investor interest in mRNA technology while highlighting the growing role

Moderna cancer vaccine research is drawing renewed attention from investors after new clinical data strengthened the outlook for the company’s personalized cancer vaccine program developed with Merck. The results have reinforced expectations that individualized mRNA vaccines could become an important

U.S. AI spending is entering a more cautious phase as companies continue pouring money into data centers, computing capacity and artificial intelligence systems while investors increasingly question whether the enormous infrastructure investments will generate sufficient returns. The debate is no